Bringing the fundamentals into focus…
Back to ARS Pharmaceuticals, Inc.
How ARS Pharmaceuticals, Inc. stacks up
SPRY · against 355 other Healthcare companies of similar size
Profitability
8/ 100
Near the bottom of its peers.
Ranked #318 of 356 · scores higher than 9% of peers
Bars: peers in each 10-point band of the profitability score44 peers with a profitability score of 0–9, including SPRY · Click a bar to see the companies
Why profitability scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on assets, return on invested capital and operating margin, which are weaker than most Healthcare peers.
- a lower return on assets: weaker than 97% of peers. Return on assets: -86.3% vs peer median 1.7%
- a lower return on invested capital: weaker than 95% of peers. Return on invested capital: -169.1% vs peer median 4.7%
- a thinner operating margin: weaker than 89% of peers. Operating margin: -185.0% vs peer median 7.1%
Metric by metric
Position: dot = SPRY, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SPRY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 321 reported | -169.1% | -0.0% | 6% | 33% | |
| Operating marginHigher is better · 330 reported | -185.0% | 2.5% | 15% | 33% | |
| Return on assetsHigher is better · 356 reported | -86.3% | -0.4% | 3% | 33% | |
| Return on equityHigher is better · 335 reported | -210.3% | -1.5% | 3% | Context only | |
| Gross marginHigher is better · 371 reported | 58.3% | 37.1% | 69% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around SPRY| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 595M USD | 99 | 97 | |
| 1 | 433M USD | 99 | 81 | |
| 1 | 578M USD | 99 | 73 | |
| 4 | 5.5B NOK (≈$523M) | 98 | 71 | |
| 4 | 261M USD | 98 | 97 | |
| 318 | 172M USD | 8 | 41 | |
| 318 | 264M USD | 8 | 30 | |
| 318 | 332M USD | 8 | 35 | |
| 318 | 334M USD | 8 | 49 | |
| 318 | 303M USD | 8 | 27 | |
| 325 | 271M USD | 7 | 14 | |
| 325 | 257M USD | 7 | 55 | |
| 325 | 475M USD | 7 | 22 | |
| 325 | 158M USD | 7 | 14 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score